Cargando…
How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis?
Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibro...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elmer Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524564/ https://www.ncbi.nlm.nih.gov/pubmed/33029271 http://dx.doi.org/10.14740/jocmr4313 |
| _version_ | 1783588566472851456 |
|---|---|
| author | da Silveira, Maria Mariana Barros Melo Cabral, Joao Victor Batista Souza, Bruno de Melo Hazime, Louis Hussein Patu Araujo, Sara Larissa de Melo Xavier, Amanda Tavares Mendes Filho, Edivaldo Bezerra Vasconcelos, Luydson Richardson da Silva Sobral Filho, Dario Celestino de Oliveira, Dinaldo Cavalcanti |
| author_facet | da Silveira, Maria Mariana Barros Melo Cabral, Joao Victor Batista Souza, Bruno de Melo Hazime, Louis Hussein Patu Araujo, Sara Larissa de Melo Xavier, Amanda Tavares Mendes Filho, Edivaldo Bezerra Vasconcelos, Luydson Richardson da Silva Sobral Filho, Dario Celestino de Oliveira, Dinaldo Cavalcanti |
| author_sort | da Silveira, Maria Mariana Barros Melo |
| collection | PubMed |
| description | Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation. |
| format | Online Article Text |
| id | pubmed-7524564 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elmer Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75245642020-10-06 How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis? da Silveira, Maria Mariana Barros Melo Cabral, Joao Victor Batista Souza, Bruno de Melo Hazime, Louis Hussein Patu Araujo, Sara Larissa de Melo Xavier, Amanda Tavares Mendes Filho, Edivaldo Bezerra Vasconcelos, Luydson Richardson da Silva Sobral Filho, Dario Celestino de Oliveira, Dinaldo Cavalcanti J Clin Med Res Review Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation. Elmer Press 2020-10 2020-09-21 /pmc/articles/PMC7524564/ /pubmed/33029271 http://dx.doi.org/10.14740/jocmr4313 Text en Copyright 2020, Silveira et al. http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Review da Silveira, Maria Mariana Barros Melo Cabral, Joao Victor Batista Souza, Bruno de Melo Hazime, Louis Hussein Patu Araujo, Sara Larissa de Melo Xavier, Amanda Tavares Mendes Filho, Edivaldo Bezerra Vasconcelos, Luydson Richardson da Silva Sobral Filho, Dario Celestino de Oliveira, Dinaldo Cavalcanti How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis? |
| title | How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis? |
| title_full | How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis? |
| title_fullStr | How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis? |
| title_full_unstemmed | How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis? |
| title_short | How Can Galectin-3 as a Biomarker of Fibrosis Improve Atrial Fibrillation Diagnosis and Prognosis? |
| title_sort | how can galectin-3 as a biomarker of fibrosis improve atrial fibrillation diagnosis and prognosis? |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524564/ https://www.ncbi.nlm.nih.gov/pubmed/33029271 http://dx.doi.org/10.14740/jocmr4313 |
| work_keys_str_mv | AT dasilveiramariamarianabarrosmelo howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT cabraljoaovictorbatista howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT souzabrunodemelo howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT hazimelouishusseinpatu howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT araujosaralarissademelo howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT xavieramandatavares howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT mendesfilhoedivaldobezerra howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT vasconcelosluydsonrichardsondasilva howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT sobralfilhodariocelestino howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis AT deoliveiradinaldocavalcanti howcangalectin3asabiomarkeroffibrosisimproveatrialfibrillationdiagnosisandprognosis |